ERBB2 and cancer: The APTneo trial is a phase 3 neoadjuvant study to evaluate atezolizumab, pertuzumab, and trastuzumab with chemotherapy (versus trastuzumab, pertuzumab, and chemotherapy) in early high-risk and locally advanced HER2-positive cancers (NCT03595592) (96).